SCHEMBL1035262

SCHEMBL1035262

Cc1ccc(Cn2c(-c3ccccc3)cc3c(F)cccc3c2=O)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 4/20 0.43
BCL2 P10415 1/20 0.41
MCL1 Q07820 1/20 0.41
GAA P10253 1/20 0.40
CNR1 P21554 1/20 0.39
ALDH1A1 P00352 4/20 0.38
GNRHR P30968 3/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
KMT2A Q03164 3/20 0.37
F11 P03951 1/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 2/20 0.37
MAPK8 P45983 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1034919 0.91 NR1H2 (0.47) CHRM1GAAALDH1A1GNRHRNR1H2
SCHEMBL1033685 0.86 ALDH1A1 (0.44) CHRM1BCL2MCL1GAACNR1
SCHEMBL1034168 0.83 BCL2 (0.43) BCL2MCL1GAACNR1ALDH1A1
SCHEMBL1031466 0.81 BCL2 (0.43) BCL2MCL1GAACNR1ALDH1A1
SCHEMBL1032972 0.81 BCL2 (0.43) BCL2MCL1GAACNR1ALDH1A1
SCHEMBL1031620 0.81 RXRA (0.42) CHRM1GAAALDH1A1NR1H2NR1H3
SCHEMBL1032940 0.80 GAA (0.40) CHRM1BCL2MCL1GAACNR1
SCHEMBL1029196 0.79 GAA (0.43) CHRM1BCL2MCL1GAAALDH1A1
SCHEMBL1033924 0.78 RXRA (0.41) CHRM1GAAALDH1A1NR1H2NR1H3
SCHEMBL1032947 0.77 CNR1 (0.40) BCL2MCL1GAACNR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572660-B1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X CEPTOR THERAPEUTICS INC (US) 2011-01-26 EP disclosed
US-20080132521-A1 Isoquinolinone Derivatives and Their Use As Therapeutic Agents EXELIXIS, INC. (US) 2008-06-05 US disclosed
US-7265131-B2 Isoquinolinone derivatives and their use as therapeutic agents EXELIXIS, INC. (US) 2007-09-04 US disclosed
EP-1572660-A1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X-Ceptor Therapeutics, Inc. (US) 2005-09-14 EP disclosed
US-20040204447-A1 Isoquinolinone derivatives and their use as therapeutic agents X-CEPTOR THERAPEUTICS INC. 2004-10-14 US disclosed
WO-2004058717-A1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X-CEPTOR THERAPEUTICS, INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132521-A1 Isoquinolinone Derivatives and Their Use As Therapeutic Agents NR1H2, NR1H3, NR1I2 CHRM1 629/4885BCL2 2456/4885MCL1 1450/4885
US-20040204447-A1 Isoquinolinone derivatives and their use as therapeutic agents NR1H2, NR1I2, NR1H3 CHRM1 1464/4885BCL2 2514/4885MCL1 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.